Testing a new treatment for a specific type of retinal dystrophy

A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy

This study is testing a new eye treatment for people aged 12 and older with a specific genetic type of retinal dystrophy to see how safe it is and how well it works.

Quick facts

• Phase: PHASE1
• Study type: Interventional
• Enrollment: 12 (estimated)
• Ages: 12 Years and up
• Sex: All
• Sponsor: PYC Therapeutics (industry)
• Locations: 5 sites (Jacksonville, Florida and 4 other locations)
• Trial ID: NCT06455826 on ClinicalTrials.gov

What this trial studies

This Phase 1 open-label study evaluates the safety and tolerability of VP-001, an intravitreal treatment, in patients with confirmed PRPF31 mutation-associated retinal dystrophy. Participants will receive multiple ascending doses of the treatment to assess its effects. The study aims to gather initial data on how well the treatment is tolerated and its potential impact on the condition. It is designed for individuals aged 12 and older who have a genetic diagnosis of the specific mutation.

Who should consider this trial

Good fit: Ideal candidates are individuals aged 12 and older with a confirmed genetic diagnosis of PRPF31 mutation and a clinical diagnosis of RP11.

Not a fit: Patients without a PRPF31 mutation or those with other forms of retinal dystrophy may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with PRPF31 mutation-associated retinal dystrophy.

How similar studies have performed: While this approach is novel for this specific mutation, similar studies targeting retinal dystrophies have shown promise in the past.

Eligibility criteria

Inclusion Criteria:

1. Male or female sex; ≥12 years of age at Baseline (Visit 2).
2. Have a molecular (genetic) diagnosis of PRPF31 mutation.
3. Have a clinical diagnosis of PRPF31 mutation-associated retinal dystrophy, that is, RP11. The following conditions are allowed for inclusion if due to RP11, if in the opinion of the investigator they will not interfere with study evaluations or have resolved: macular edema (intraretinal, sub-retinal or other fluid) requiring regular treatment at a frequency of less than every 6 weeks; macular edema must be stable for at least 3 months prior to Screening (Visit 1). The investigator must consult with the study Medical Monitor.
4. If ≥18 years of age, understand the language of the informed consent and are willing and able to provide written informed consent prior to any study procedures. If a minor (12 to \<18 years of age), a parent or legal guardian willing and able to provide written permission for the minor's participation prior to performing any study related procedures and pediatric participant able to provide age appropriate assent for study participation.
5. If ≥18 years of age, are willing to comply with the instructions and attend all scheduled study visits. If a minor (12 to \<18 years of age), able to complete all study assessments, comply with the protocol, and has a parent or caregiver willing and able to follow study instructions and attend study visits with the participant as required, in the opinion of the Investigator.
6. Meets ≥1 of the following for visual function in the study eye:

   1. V4e visual field \>1000 deg2, per kinetic perimetry
   2. \<Mean microperimetry threshold: \>5 decibel (dB) to \<15dB
   3. Visual acuity: 20/40 to 20/200 inclusive (\>35 and \<70 letters by Early-Treatment Diabetic Retinopathy Study \[ETDRS\])
   4. Ellipsoid zone (EZ) length \>1000 microns, of which 500 microns is contiguous, by SD-OCT
   5. FST baseline no worse than -20 dB
7. Participants of childbearing potential and male participants must not be pregnant or lactating and must be sexually inactive by abstinence, which is consistent with the preferred and usual lifestyle of the participant or agree to use adequate birth control throughout study duration. Adequate birth control is defined as hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a condom or diaphragm; intrauterine device (IUD); or surgical sterilization of partner. For nonsexually active participants, abstinence may be regarded as an adequate method of birth control. Participants of childbearing potential include all participants who have experienced menarche and have not undergone successful surgical sterilization (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) or are not postmenopausal (12 months after last menses).

Exclusion Criteria:

1. Have any uncontrolled systemic disease that, in the opinion of the Investigator, would preclude participation in the study that include but are not limited to infection, uncontrolled elevated blood pressure, cardiovascular disease, or glycemic control issues, or any other medical condition that may put the participant at risk due to study procedures.
2. Mutations in genes that cause autosomal dominant RP, Xlinked RP, or presence of biallelic mutations in autosomal recessive RP/retinal dystrophy genes other than PRPF31 mutations.
3. Have used anti-vascular endothelial growth factor (VEGF) agents within 2 months or corticosteroid injections within the last 3 months.
4. Have had Ozurdex

   * implants placed within 3 months or Retisert
   * or Iluvien
   * implants placed within 3 years prior to Baseline (Visit 2).
5. Within 3 months prior to Baseline (Visit 2), have undergone any vitreoretinal surgery (scleral buckle, pars plana vitrectomy, retrieval of a dropped nucleus or intraocular lens, radial optic neurotomy, sheathotomy, cyclodestructive procedures or multiple filtration surgeries \[2 or more\]) or any other ocular surgery.
6. Have ocular media opacity or poor pupillary dilation prohibiting quality ophthalmic evaluation or photography, as assessed by the investigator.
7. Have used any investigational drug or device within 90 days or 5 estimated half-lives of Baseline (Visit 2), whichever is longer, or plan to participate in another study of drug or device during the study period. Participation in observational trials is allowable based on investigator discretion and consultation with the Medical Monitor. It is assumed that the observational trial evaluations would not interfere with participation in this study.
8. Have received any prior cell, ribonucleic acid (RNA) (including VP-001), or gene therapy for a retinal condition.
9. Have a recent history (\<6 months) or current excessive recreational drug or alcohol use, in the opinion of the investigator.
10. Any retinal pathology other than RP11 that in the investigator's opinion could affect study results.
11. Participants should not have any conditions, in the investigator's opinion, that may put the participant at increased risk, confound study data, or interfere significantly with the participant's study participation.

Where this trial is running

Jacksonville, Florida and 4 other locations

• University of Florida Health — Jacksonville, Florida, United States (RECRUITING)
• University of Michigan Kellogg Eye Center — Ann Arbor, Michigan, United States (RECRUITING)
• Oregon Health and Science University - Casey Eye Institute — Portland, Oregon, United States (RECRUITING)
• Retina Foundation of the Southwest — Dallas, Texas, United States (RECRUITING)
• Baylor College of Medicine- Alkek Eye Center — Houston, Texas, United States (RECRUITING)

Study contacts

• Study coordinator: Ora Inc

Conditions: Retinitis Pigmentosa 11, Retinal Degeneration, Eye Diseases, Retinal Disease, Retinal Dystrophies